血管内碎石术与药物涂层球囊血管成形术治疗严重钙化股总动脉粥样硬化性疾病
这项回顾性单中心单臂研究纳入2017年2月至2020年9月连续接受血管内碎石术(IVL)联合药物涂层球囊(DCB)治疗的33例钙化股总动脉病变患者,评估12个月结局。手术技术成功率为97%,12个月一期通畅率为72%,免于靶病变血运重建率为94%,二期通畅率为88%,12个月生存率为100%。作者认为该联合治疗围手术期并发症风险低、12个月临床结局可接受且再干预率低。
要点
- 33例钙化股总动脉病变患者接受IVL联合DCB治疗,手术技术成功率为97%。
- 12个月一期通畅率为72%,免于靶病变血运重建率为94%,二期通畅率为88%。
- 围手术期限流性夹层2例(6%),外周栓塞1例(3%),补救性支架置入率为12%。
核心结论
- 作者认为,IVL联合DCB治疗钙化股总动脉病变与较低的围手术期并发症风险、可接受的12个月临床结局和较低的再干预率相关。
研究设计与样本
- 回顾性单中心单臂研究,连续纳入2017年2月至2020年9月接受IVL联合DCB治疗的钙化股总动脉病变患者33例。
主要发现
- 手术技术成功(残余狭窄<30%)率为97%(n=32)。
- 术后限流性夹层2例(6%),外周栓塞1例(3%),补救性支架置入率为12%(n=4),未观察到穿孔。
- 中位住院时间为2天(四分位距2-3天)。
- 12个月时一期通畅率为72%,免于靶病变血运重建率为94%,二期通畅率为88%,12个月生存率为100%,75%(n=25)的患者无症状或表现为轻度跛行。
- 慢性肢体威胁性缺血(HR 0.92,95%CI 0.18-4.8,p=0.7)、慢性肾脏病(HR 1.30,95%CI 0.29-5.8,p=0.72)、使用7 mm IVL导管(HR 0.59,95%CI 0.13-2.63,p=0.49)或高剂量DCB(HR 0.68,95%CI 0.13-3.53,p=0.65)均未影响一期通畅率。
临床怎么用
- 作者认为,IVL联合DCB血管成形术可作为经过高度选择的股总动脉粥样硬化性疾病患者的外科手术替代方案。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Intravascular lithotripsy (IVL) followed by drug-coated balloon (DCB) angioplasty might be a valuable alternative to surgery for calcified common femoral artery (CFA) atherosclerotic disease. Nonetheless, the 12 months performance of this treatment strategy remains unknown. This study reports on the 12 months outcomes of IVL with adjunctive DCB angioplasty for calcified CFA lesions. METHODS: This is a retrospective single-center, single-arm study. Consecutive patients treated by IVL and DCB for calcified CFA disease between February 2017 and September 2020 were evaluated. The primary measure outcome of this analysis was primary patency. Procedural technical success (<30% stenosis), freedom from target lesion revascularization (TLR), secondary patency, and overall mortality were additionally analyzed. RESULTS: Thirty-three (n=33) patients were included in this study. The majority presented with lifestyle limiting claudication (n=20, 61%), 52% (n=17) of the patients had chronic kidney disease (CKD) and 33% (n=11) had diabetes. The procedural technical success was 97% (n=32). A flow-limiting dissection post IVL was observed in 2 patients (6%) and a peripheral embolization in a single patient (3%), while the bail-out stenting rate amounted to 12% (n=4). No perforation was observed. The median length of hospital stay was 2 days (interquartile range 2-3). At 12 months, the primary patency was 72%. The freedom from TLR and the secondary patency rates were 94% and 88%, respectively. The 12-month survival amounted to 100% and 75% (n=25) of the patients were asymptomatic or presented with mild claudication. The presence of chronic limb-threatening ischemia (CLTI) (hazard ratio [HR], 0.92; confidence interval (CI); 0.18-4.8, p=0.7) or CKD (HR, 1.30; 95% CI, 0.29-5.8; p=0.72), as well as the use of a 7 mm IVL catheter (HR, 0.59; 95% CI, 0.13-2.63; p=0.49) or of high-dose DCB (HR, 0.68; 95% CI, 0.13-3.53; p=0.65) did not influence the primary patency. CONCLUSIONS: In this study, the combination of IVL and DCB angioplasty for calcified CFA disease was associated with low risk for periprocedural complications, acceptable 12 months clinical outcomes, and low rates of reinterventions. CLINICAL IMPACT: Intravascular lithotripsy in combination with DCB angioplasty can be an alternative to surgery in highly selected patients with CFA atherosclerotic disease. In this Cohort the combination therapy lead to acceptable clinical results and low reintervention rates at 12 months.
引用
- Stavroulakis K, Torsello G, Chlouverakis G, et al. Intravascular Lithotripsy and Drug-Coated Balloon Angioplasty for Severely Calcified Common Femoral Artery Atherosclerotic Disease. J Endovasc Ther. 2023. PMID: 36896876. doi:10.1177/15266028231158313
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。